Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then please contact the research committee so that we can disseminate these to the membership. Authors who are BOPA members are in bold.

Manuscripts

Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study

L Steventon, S Nicum, K Man, D Dodwell, Z Wang, A Patel, ... Chambers P

ESMO Real World Data and Digital Oncology

2025

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice

G Sandhu, J Adattini, EA Gordon, N O’Neill, C Bagnis, AV Boddy, …Chambers P, Morris E

eClinicalMedicine

2025

A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function

G Sandhu, EA Gordon, J Adattini, N O’Neill, P Chambers, DW Johnson, …

eClinicalMedicine

2025

Scoping review identifying interventions that have been tested to optimise the experience of people from ethnic minority groups receiving systemic anticancer therapy (SACT)

J McLean, P Chambers, L Steventon, S Cruickshank, S Nabhani-Gebara

BMJ Quality & Safety

2025

Enablers and barriers of clinical trial participation in adult patients from minority ethnic groups: a systematic review

GA Alarcón Garavito, K Gilchrist, C Ciurtin, S Khanna, P Chambers, …

Trials 26 (1), 65

 

Editorials
Shaping the UK’s long term relationship with tirzepatide

Peter Robertson, Nicholas Browne

BMJ 2025;388:r394  doi: https://doi.org/10.1136/bmj.r394
(Peter is a BOPA CPCP Subcommittee member)

 

 

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article